{
    "xml": "<topic id=\"PHP34585\" outputclass=\"drugClass\" rev=\"1.24\" type=\"drugClass\" namespace=\"/drug-classes/epoetins\" basename=\"epoetins\" title=\"EPOETINS\">\n<title>EPOETINS</title>\n<topic id=\"PHP55530\" outputclass=\"importantSafetyInformation\" rev=\"1.10\" parent=\"/drug-classes/epoetins\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">MHRA/CHM advice (December 2007) Erythropoietins&#8212;haemoglobin concentration</p>\n<p>Overcorrection of haemoglobin concentration in patients with chronic kidney disease may increase the risk of death and serious cardiovascular events, and in patients with cancer may increase the risk of thrombosis and related complications:</p>\n<ul>\n<li>patients should not be treated with erythropoietins for the licensed indications in chronic kidney disease or cancer in patients receiving chemotherapy <i>unless</i> symptoms of anaemia are present</li>\n<li>the haemoglobin concentration should be maintained within the range 10&#8211;12&#8239;g/100&#8239;mL</li>\n<li>haemoglobin concentrations higher than 12&#8239;g/100&#8239;mL should be avoided</li>\n<li>the aim of treatment is to relieve symptoms of anaemia, and in patients with chronic kidney disease to avoid the need for blood transfusion; the haemoglobin concentration should not be increased beyond that which provides adequate control of symptoms of anaemia (in some patients, this may be achieved at concentrations lower than the recommended range)</li>\n</ul>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">MHRA/CHM advice (December 2007 and July 2008) Erythropoietins&#8212;tumour progression and survival in patients with cancer</p>\n<p>Clinical trial data show an unexplained excess mortality and increased risk of tumour progression in patients with anaemia associated with cancer who have been treated with erythropoietins. Many of these trials used erythropoietins outside of the licensed indications (i.e. overcorrected haemoglobin concentration or given to patients who have not received chemotherapy):</p>\n<ul>\n<li>erythropoietins licensed for the treatment of <i>symptomatic</i> anaemia associated with cancer, are licensed only for patients who are receiving chemotherapy</li>\n<li>the decision to use erythropoietins should be based on an assessment of the benefits and risks for individual patients; blood transfusion may be the preferred treatment for anaemia associated with cancer chemotherapy, particularly in those with a good cancer prognosis</li>\n</ul>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55547\" outputclass=\"contraindications\" rev=\"1.8\" parent=\"/drug-classes/epoetins\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Patients unable to receive thromboprophylaxis</ph>; <ph outputclass=\"contraindication\">pure red cell aplasia following erythropoietin therapy</ph>; <ph outputclass=\"contraindication\">uncontrolled hypertension</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55562\" outputclass=\"cautions\" rev=\"1.26\" parent=\"/drug-classes/epoetins\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Aluminium toxicity (can impair the response to erythropoietin)</ph>; <ph outputclass=\"caution\">concurrent infection (can impair the response to erythropoietin)</ph>; <ph outputclass=\"caution\">correct factors that contribute to the anaemia of chronic renal failure, such as iron or folate deficiency, before treatment.</ph>; <ph outputclass=\"caution\">during dialysis (increase in unfractionated or low molecular weight heparin dose may be needed)</ph>; <ph outputclass=\"caution\">epilepsy</ph>; <ph outputclass=\"caution\">inadequately treated or poorly controlled blood pressure&#8212;interrupt treatment if blood pressure uncontrolled</ph>; <ph outputclass=\"caution\">ischaemic vascular disease</ph>; <ph outputclass=\"caution\">malignant disease</ph>; <ph outputclass=\"caution\">other inflammatory disease (can impair the response to erythropoietin)</ph>; <ph outputclass=\"caution\">risk of thrombosis may be increased when used for anaemia before orthopaedic surgery&#8212;avoid in cardiovascular disease including recent myocardial infarction or cerebrovascular accident</ph>; <ph outputclass=\"caution\">risk of thrombosis may be increased when used for anaemia in adults receiving cancer chemotherapy</ph>; <ph outputclass=\"caution\">sickle-cell disease (lower target haemoglobin concentration may be appropriate)</ph>; <ph outputclass=\"caution\">sudden stabbing migraine-like pain (warning of a hypertensive crisis)</ph>; <ph outputclass=\"caution\">thrombocytosis (monitor platelet count for first 8 weeks)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55439\" outputclass=\"sideEffects\" rev=\"1.27\" parent=\"/drug-classes/epoetins\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Aggravation of hypertension (dose-dependent)</ph>; <ph outputclass=\"sideEffect\">cardiovascular events</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dose-dependent increase in platelet count regressing during treatment (but thrombocytosis rare)</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hypertensive crisis (in isolated patients with normal or low blood pressure)</ph>; <ph outputclass=\"sideEffect\">increase in blood pressure (dose-dependent)</ph>; <ph outputclass=\"sideEffect\">influenza-like symptoms (may be reduced if intravenous injection given over 5 minutes)</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">shunt thrombosis especially if tendency to hypotension or arteriovenous shunt complications</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"veryRare\">\n<p outputclass=\"title\">Very rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Sudden loss of efficacy because of pure red cell aplasia, particularly following subcutaneous administration in patients with chronic renal failure</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anaphylaxis</ph>; <ph outputclass=\"sideEffect\">angioedema</ph>; <ph outputclass=\"sideEffect\">hyperkalaemia</ph>; <ph outputclass=\"sideEffect\">hypersensitivity reactions</ph>; <ph outputclass=\"sideEffect\">injection-site reactions</ph>; <ph outputclass=\"sideEffect\">peripheral oedema</ph>; <ph outputclass=\"sideEffect\">skin reactions</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Hypertensive crisis</p>\n<p>In isolated patients with normal or low blood pressure, hypertensive crisis with encephalopathy-like symptoms and generalised tonic-clonic seizures requiring immediate medical attention has occured with epoetin.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Pure red cell aplasia</p>\n<p>There have been very rare reports of pure red cell aplasia in patients treated with erythropoietins. In patients who develop a lack of efficacy with erythropoietin therapy and with a diagnosis of pure red cell aplasia, treatment with erythropoietins must be discontinued and testing for erythropoietin antibodies considered. Patients who develop pure red cell aplasia should <b>not</b> be switched to another form of erythropoietin.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP55403\" outputclass=\"monitoringRequirements\" parent=\"/drug-classes/epoetins\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor closely blood pressure, reticulocyte counts, haemoglobin, and electrolytes&#8212;interrupt treatment if blood pressure uncontrolled.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Other factors, such as iron or folate deficiency, that contribute to the anaemia of chronic renal failure should be corrected before treatment and monitored during therapy. Supplemental iron may improve the response in resistant patients.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugClasses\" href=\"#drugClasses\" title=\"Drug classes\" namespace=\"/drug-classes\">Drug classes</xref>\n</parents>\n<drugs>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP5886\" title=\"DARBEPOETIN ALFA\" namespace=\"/drugs/darbepoetin-alfa\">DARBEPOETIN ALFA</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP96719\" title=\"EPOETIN ALFA\" namespace=\"/drugs/epoetin-alfa\">EPOETIN ALFA</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP96720\" title=\"EPOETIN BETA\" namespace=\"/drugs/epoetin-beta\">EPOETIN BETA</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP96722\" title=\"EPOETIN ZETA\" namespace=\"/drugs/epoetin-zeta\">EPOETIN ZETA</xref>\n</drugs>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#drugClasses\" href=\"#drugClasses\" namespace=\"/drug-classes\" title=\"Drug classes\" count=\"1\" rel=\"link\">Drug classes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP5886\" namespace=\"/drugs/darbepoetin-alfa\" title=\"DARBEPOETIN ALFA\" count=\"1\" rel=\"link\">DARBEPOETIN ALFA</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP96719\" namespace=\"/drugs/epoetin-alfa\" title=\"EPOETIN ALFA\" count=\"1\" rel=\"link\">EPOETIN ALFA</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP96720\" namespace=\"/drugs/epoetin-beta\" title=\"EPOETIN BETA\" count=\"1\" rel=\"link\">EPOETIN BETA</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP96722\" namespace=\"/drugs/epoetin-zeta\" title=\"EPOETIN ZETA\" count=\"1\" rel=\"link\">EPOETIN ZETA</xref>\n</links>\n</topic>",
    "id": "PHP34585",
    "outputclass": "drugClass",
    "rev": "1.24",
    "type": "drugClass",
    "namespace": "/drug-classes/epoetins",
    "basename": "epoetins",
    "title": "EPOETINS",
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "MHRA/CHM advice (December 2007) Erythropoietins&#8212;haemoglobin concentration",
                "textContent": "Overcorrection of haemoglobin concentration in patients with chronic kidney disease may increase the risk of death and serious cardiovascular events, and in patients with cancer may increase the risk of thrombosis and related complications:\n\npatients should not be treated with erythropoietins for the licensed indications in chronic kidney disease or cancer in patients receiving chemotherapy unless symptoms of anaemia are present the haemoglobin concentration should be maintained within the range 10&#8211;12 g/100 mL haemoglobin concentrations higher than 12 g/100 mL should be avoided the aim of treatment is to relieve symptoms of anaemia, and in patients with chronic kidney disease to avoid the need for blood transfusion; the haemoglobin concentration should not be increased beyond that which provides adequate control of symptoms of anaemia (in some patients, this may be achieved at concentrations lower than the recommended range)",
                "html": "<p>Overcorrection of haemoglobin concentration in patients with chronic kidney disease may increase the risk of death and serious cardiovascular events, and in patients with cancer may increase the risk of thrombosis and related complications:</p><ul>\n<li>patients should not be treated with erythropoietins for the licensed indications in chronic kidney disease or cancer in patients receiving chemotherapy <i>unless</i> symptoms of anaemia are present</li>\n<li>the haemoglobin concentration should be maintained within the range 10&#8211;12&#8239;g/100&#8239;mL</li>\n<li>haemoglobin concentrations higher than 12&#8239;g/100&#8239;mL should be avoided</li>\n<li>the aim of treatment is to relieve symptoms of anaemia, and in patients with chronic kidney disease to avoid the need for blood transfusion; the haemoglobin concentration should not be increased beyond that which provides adequate control of symptoms of anaemia (in some patients, this may be achieved at concentrations lower than the recommended range)</li>\n</ul>"
            },
            {
                "type": "importantSafetyInformation",
                "title": "MHRA/CHM advice (December 2007 and July 2008) Erythropoietins&#8212;tumour progression and survival in patients with cancer",
                "textContent": "Clinical trial data show an unexplained excess mortality and increased risk of tumour progression in patients with anaemia associated with cancer who have been treated with erythropoietins. Many of these trials used erythropoietins outside of the licensed indications (i.e. overcorrected haemoglobin concentration or given to patients who have not received chemotherapy):\n\nerythropoietins licensed for the treatment of symptomatic anaemia associated with cancer, are licensed only for patients who are receiving chemotherapy the decision to use erythropoietins should be based on an assessment of the benefits and risks for individual patients; blood transfusion may be the preferred treatment for anaemia associated with cancer chemotherapy, particularly in those with a good cancer prognosis",
                "html": "<p>Clinical trial data show an unexplained excess mortality and increased risk of tumour progression in patients with anaemia associated with cancer who have been treated with erythropoietins. Many of these trials used erythropoietins outside of the licensed indications (i.e. overcorrected haemoglobin concentration or given to patients who have not received chemotherapy):</p><ul>\n<li>erythropoietins licensed for the treatment of <i>symptomatic</i> anaemia associated with cancer, are licensed only for patients who are receiving chemotherapy</li>\n<li>the decision to use erythropoietins should be based on an assessment of the benefits and risks for individual patients; blood transfusion may be the preferred treatment for anaemia associated with cancer chemotherapy, particularly in those with a good cancer prognosis</li>\n</ul>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Patients unable to receive thromboprophylaxis",
                "html": "Patients unable to receive thromboprophylaxis"
            },
            {
                "type": "contraindications",
                "textContent": "pure red cell aplasia following erythropoietin therapy",
                "html": "pure red cell aplasia following erythropoietin therapy"
            },
            {
                "type": "contraindications",
                "textContent": "uncontrolled hypertension",
                "html": "uncontrolled hypertension"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Aluminium toxicity (can impair the response to erythropoietin)",
                "html": "Aluminium toxicity (can impair the response to erythropoietin)"
            },
            {
                "type": "cautions",
                "textContent": "concurrent infection (can impair the response to erythropoietin)",
                "html": "concurrent infection (can impair the response to erythropoietin)"
            },
            {
                "type": "cautions",
                "textContent": "correct factors that contribute to the anaemia of chronic renal failure, such as iron or folate deficiency, before treatment.",
                "html": "correct factors that contribute to the anaemia of chronic renal failure, such as iron or folate deficiency, before treatment."
            },
            {
                "type": "cautions",
                "textContent": "during dialysis (increase in unfractionated or low molecular weight heparin dose may be needed)",
                "html": "during dialysis (increase in unfractionated or low molecular weight heparin dose may be needed)"
            },
            {
                "type": "cautions",
                "textContent": "epilepsy",
                "html": "epilepsy"
            },
            {
                "type": "cautions",
                "textContent": "inadequately treated or poorly controlled blood pressure&#8212;interrupt treatment if blood pressure uncontrolled",
                "html": "inadequately treated or poorly controlled blood pressure&#8212;interrupt treatment if blood pressure uncontrolled"
            },
            {
                "type": "cautions",
                "textContent": "ischaemic vascular disease",
                "html": "ischaemic vascular disease"
            },
            {
                "type": "cautions",
                "textContent": "malignant disease",
                "html": "malignant disease"
            },
            {
                "type": "cautions",
                "textContent": "other inflammatory disease (can impair the response to erythropoietin)",
                "html": "other inflammatory disease (can impair the response to erythropoietin)"
            },
            {
                "type": "cautions",
                "textContent": "risk of thrombosis may be increased when used for anaemia before orthopaedic surgery&#8212;avoid in cardiovascular disease including recent myocardial infarction or cerebrovascular accident",
                "html": "risk of thrombosis may be increased when used for anaemia before orthopaedic surgery&#8212;avoid in cardiovascular disease including recent myocardial infarction or cerebrovascular accident"
            },
            {
                "type": "cautions",
                "textContent": "risk of thrombosis may be increased when used for anaemia in adults receiving cancer chemotherapy",
                "html": "risk of thrombosis may be increased when used for anaemia in adults receiving cancer chemotherapy"
            },
            {
                "type": "cautions",
                "textContent": "sickle-cell disease (lower target haemoglobin concentration may be appropriate)",
                "html": "sickle-cell disease (lower target haemoglobin concentration may be appropriate)"
            },
            {
                "type": "cautions",
                "textContent": "sudden stabbing migraine-like pain (warning of a hypertensive crisis)",
                "html": "sudden stabbing migraine-like pain (warning of a hypertensive crisis)"
            },
            {
                "type": "cautions",
                "textContent": "thrombocytosis (monitor platelet count for first 8 weeks)",
                "html": "thrombocytosis (monitor platelet count for first 8 weeks)"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Aggravation of hypertension (dose-dependent)",
                        "html": "Aggravation of hypertension (dose-dependent)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "cardiovascular events",
                        "html": "cardiovascular events",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dose-dependent increase in platelet count regressing during treatment (but thrombocytosis rare)",
                        "html": "dose-dependent increase in platelet count regressing during treatment (but thrombocytosis rare)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypertensive crisis (in isolated patients with normal or low blood pressure)",
                        "html": "hypertensive crisis (in isolated patients with normal or low blood pressure)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "increase in blood pressure (dose-dependent)",
                        "html": "increase in blood pressure (dose-dependent)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "influenza-like symptoms (may be reduced if intravenous injection given over 5 minutes)",
                        "html": "influenza-like symptoms (may be reduced if intravenous injection given over 5 minutes)",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "shunt thrombosis especially if tendency to hypotension or arteriovenous shunt complications",
                        "html": "shunt thrombosis especially if tendency to hypotension or arteriovenous shunt complications",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "veryRare": [
                    {
                        "type": "veryRare",
                        "textContent": "Sudden loss of efficacy because of pure red cell aplasia, particularly following subcutaneous administration in patients with chronic renal failure",
                        "html": "Sudden loss of efficacy because of pure red cell aplasia, particularly following subcutaneous administration in patients with chronic renal failure",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Anaphylaxis",
                        "html": "Anaphylaxis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "angioedema",
                        "html": "angioedema",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperkalaemia",
                        "html": "hyperkalaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypersensitivity reactions",
                        "html": "hypersensitivity reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "injection-site reactions",
                        "html": "injection-site reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "peripheral oedema",
                        "html": "peripheral oedema",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "skin reactions",
                        "html": "skin reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Hypertensive crisis",
                "textContent": "In isolated patients with normal or low blood pressure, hypertensive crisis with encephalopathy-like symptoms and generalised tonic-clonic seizures requiring immediate medical attention has occured with epoetin.",
                "html": "<p>In isolated patients with normal or low blood pressure, hypertensive crisis with encephalopathy-like symptoms and generalised tonic-clonic seizures requiring immediate medical attention has occured with epoetin.</p>"
            },
            {
                "type": "advice",
                "title": "Pure red cell aplasia",
                "textContent": "There have been very rare reports of pure red cell aplasia in patients treated with erythropoietins. In patients who develop a lack of efficacy with erythropoietin therapy and with a diagnosis of pure red cell aplasia, treatment with erythropoietins must be discontinued and testing for erythropoietin antibodies considered. Patients who develop pure red cell aplasia should not be switched to another form of erythropoietin.",
                "html": "<p>There have been very rare reports of pure red cell aplasia in patients treated with erythropoietins. In patients who develop a lack of efficacy with erythropoietin therapy and with a diagnosis of pure red cell aplasia, treatment with erythropoietins must be discontinued and testing for erythropoietin antibodies considered. Patients who develop pure red cell aplasia should <b>not</b> be switched to another form of erythropoietin.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor closely blood pressure, reticulocyte counts, haemoglobin, and electrolytes&#8212;interrupt treatment if blood pressure uncontrolled.",
                "html": "<p>Monitor closely blood pressure, reticulocyte counts, haemoglobin, and electrolytes&#8212;interrupt treatment if blood pressure uncontrolled.</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "Other factors, such as iron or folate deficiency, that contribute to the anaemia of chronic renal failure should be corrected before treatment and monitored during therapy. Supplemental iron may improve the response in resistant patients.",
                "html": "<p>Other factors, such as iron or folate deficiency, that contribute to the anaemia of chronic renal failure should be corrected before treatment and monitored during therapy. Supplemental iron may improve the response in resistant patients.</p>"
            }
        ]
    },
    "drugsInClass": [
        {
            "id": "PHP5886",
            "label": "DARBEPOETIN ALFA",
            "type": "drug"
        },
        {
            "id": "PHP96719",
            "label": "EPOETIN ALFA",
            "type": "drug"
        },
        {
            "id": "PHP96720",
            "label": "EPOETIN BETA",
            "type": "drug"
        },
        {
            "id": "PHP96722",
            "label": "EPOETIN ZETA",
            "type": "drug"
        }
    ],
    "backlinks": {},
    "links": {
        "#drugClasses": [
            {
                "id": "drugClasses",
                "label": "Drug classes",
                "type": "#drugClasses"
            }
        ],
        "drug": [
            {
                "id": "PHP5886",
                "label": "DARBEPOETIN ALFA",
                "type": "drug"
            },
            {
                "id": "PHP96719",
                "label": "EPOETIN ALFA",
                "type": "drug"
            },
            {
                "id": "PHP96720",
                "label": "EPOETIN BETA",
                "type": "drug"
            },
            {
                "id": "PHP96722",
                "label": "EPOETIN ZETA",
                "type": "drug"
            }
        ]
    }
}